



Florida Power

CORPORATION

Crystal River Unit 3

Docket No. 50-302

February 25, 1994
3F0294-09

U. S. Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, D. C. 20555

Subject: 10 CFR 26, Fitness-For-Duty Program Performance Data
(6 Month Report)

Dear Sir:

Florida Power Corporation (FPC) hereby submits its Fitness-For-Duty (FFD) program performance data for the period of July 1, 1993 through December 31, 1993. FPC is required to submit this report within sixty (60) days after each six month reporting period in accordance with 10 CFR 26.71(d).

Sincerely,

P. M. Beard, Jr.
Senior Vice President
Nuclear Operations

PMB/GMF

Attachment

xc: Regional Administrator, Region II
Senior Resident Inspector
NRR Project Manager

030005

A021
11

GENERAL OFFICE: 3201 Thirty-fourth Street South • P.O. Box 14042 • St. Petersburg, Florida 33733 • (813) 866-5151

Florida Progress Company

9403080315 940225
PDR ADOCK 05000302
R PDR

Fitness for Duty Program Performance Data Personnel Subject to 10CFR 26

<u>Florida Power Corporation (FPC)/Crystal River Unit 3</u> <small>Company</small>	<u>December 31, 1993</u> <small>6 Months Ending</small>
<u>St. Petersburg, Florida / Crystal River, Florida</u> <small>Location</small>	
<u>Dr. Ronald S. Kline</u> <small>Contact Name</small>	<u>(813) 866-5277</u> <small>Phone (include area code)</small>

Cutoffs: Screen/Confirmation (ng/ml) Appendix A to 10CFR 26

Marijuana	50 / 15	Amphetamines	/	<u>See Comment</u>	/
Cocaine	/	Phencyclidine	/	_____	/
Opiates	/	Alcohol (% BAC)	/	_____	/

Testing Results		Licensee Employees		Long-Term Contractor Personnel		Short-Term Contractor Personnel	
		# Tested	# Positive	# Tested	# Positive	# Tested	# Positive
Average Number with Unescorted Access		939		N/A		239	
Pre-Access		46	0	N/A	N/A	80	0
For Cause	Post accident	N/A	N/A	N/A	N/A	N/A	N/A
	Observed behavior	0	0	N/A	N/A	0	0
Random		507	0	N/A	N/A	106	0
Follow-up		N/A	N/A	N/A	N/A	N/A	N/A
Other		N/A	N/A	N/A	N/A	N/A	N/A
Total		553	0	N/A	N/A	186	0

COMMENT:

The five (5) substances listed below are additional substances used by FPC for Pre-access, For-cause, and Follow-up testing only.

	<u>Screened (ng/ml)</u>	<u>Confirmatory (ng/ml)</u>
1. Barbiturates	300	200
2. Benzodiazepines	300	200
3. Methadone	300	200
4. Methaqualone	300	200
5. Propoxyphene	300	200

Breakdown of Confirmed Positive Tests for Specific Substances

	Marijuana	Cocaine	Opiates	Amphetamines	Phencyclidine	Alcohol	Refusal to Test	1	2	3	4	5	
Licensee Employees	0 /					0	0						
Long-Term Contractors													
Short-Term Contractors	0 /	0				0	0						
Total	0	0				0	0						0

(The left side of the diagonally split column represents test results that would have been positive at the NRC cutoff level. The right side represents the number of MRO confirmed positives based on FPC's more restrictive cutoff level.)

Program Performance Data

1. Random Test Rate = $\frac{\text{Total tested}}{\text{Total in Pool}} = \frac{553 + 186}{939 + 239} = \frac{739}{1178} \times 100 = 62.73\%$
for 6 months

(NOTE: Random testing rate is 100% per year.)

- | | | |
|----|---|------------------------------|
| 2. | Drugs tested for and cutoff levels. | See Table |
| 3. | Workforce population tested. | See Table |
| 4. | • Number of tests and results by population | See Table |
| | • Process stage | Lab & confirmatory screening |
| | • Type of test | See Table |
| 5. | Substances identified. | See Table |
| 6. | Number of temporary suspensions or other administrative actions taken based on on-site presumptive positives for marijuana (THC) and for cocaine. | N/A |

SUMMARY OF MANAGEMENT ACTIONS

INITIATIVES TAKEN: N/A

LESSONS LEARNED: N/A

EFFECTIVENESS EVALUATION:

During this 6 month period, FPC tested 739 employees including contractors (random, pre-access, and for-cause) and no positive results were identified (0.0%).

PROGRAM WEAKNESS: N/A

CORRECTIVE ACTIONS: N/A

AUDIT SUMMARY

Doctors & Physicians Laboratory which performed the drug screening tests required by 10 CFR 26 for FPC was purchased by SmithKline Beecham Clinical Laboratories during the last quarter of 1993. Because of this purchase, FPC performed an evaluation to assure the laboratory continued to meet the requirements of the FFD performance objectives.

It was determined that the organizational changes occurred only at the ownership level and did not affect the day-to-day operation of the laboratory. The facility continues to be NIDA certified with the last inspection occurring in August of 1993.

SUMMARY LISTING OF EVENTS REPORTED

On July 20, 1993, a blind specimen submitted by FPC to its contract laboratory was erroneously reported as negative when, in fact, the specimen contained methadone. This was characterized as a "false negative" and was reported to the NRC on August 9, 1993.

Date specimen submitted:	7/20/93
Date specimen received at laboratory:	7/21/93
Date of report:	7/21/93
Date report reviewed by MRO:	7/21/93
How discovered:	Review of the laboratory report by the MRO found the mistake.
Substance detected:	None. (Methadone should have been detected and was not).
Management actions:	FPC requested the laboratory to investigate the error and retest the sample.
Findings/Results:	Upon retest, the laboratory correctly identified the substance as methadone. The follow-up laboratory investigation revealed that the error was due to an instrument failure which could not be reproduced a second time. It was determined that the instrument failed to pick up the correct amount of urine specimen, which caused a low creatinine value and the negative result.
Corrective actions:	Since this appeared to be a random instrument error, there were no specific corrective actions. The lab reported that all quality control checks and periodic maintenance of this particular instrument have been done.